Elbasvir and grazoprevir for the treatment of hepatitis C

被引：3

作者：

Wang, Szu-Jen ^{[1
,2
]}

Huang, Chung-Feng ^{[3
,4
]}

Yu, Ming-Lung ^{[1
,3
,4
]}

机构：

[1] Kaohsiung Med Univ, Grad Inst Clin Med, Kaohsiung, Taiwan

[2] Yuans Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung, Taiwan

[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung 807, Taiwan

[4] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Kaohsiung, Taiwan

来源：

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | 2021年 / 19卷 / 09期

关键词：

Direct-acting antivirals; elbasvir; grazoprevir; hepatitis C virus; genotype; 1; or; 4; sustained viral response; efficacy; safety; tolerability; drug-drug interaction; VIRUS GENOTYPE 1; HCV NS5A INHIBITOR; INFECTION; ELBASVIR/GRAZOPREVIR; ASSOCIATION; EFFICACY; MK-8742; SAFETY; TRANSPLANTATION; COINFECTION;

D O I：

10.1080/14787210.2021.1874351

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a sustained virological response rate >95% in different populations. Area covered: This review summarizes the pharmacokinetics, pharmacodynamics, efficacy, and safety of Elbasvir/Grazoprevir (EBR/GZR). Expert opinion: EBR/GZR is a combination of NS5A and NS3/4A inhibitors. The performance in the EBR/GZR combination's safety and tolerability is appreciated in clinical treatment. EBR/GZR also has a higher barrier to resistance-associated substitutions. Based on clinical trials and real-world experience, elbasvir/grazoprevir is effective in the HCV GT1, 4 infections.

引用

页码：1071 / 1081

页数：11

共 50 条

[21] Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease
Reddy, K. Rajender
Roth, David
Bruchfeld, Annette
Hwang, Peggy
Haber, Barbara
Robertson, Michael N.
Barr, Eliav
Greaves, Wayne
HEPATOLOGY RESEARCH, 2017, 47 (12) : 1340 - 1345
[22] Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection
Puenpatom, Amy
Cao, Yumei
Yu, Xian
Kanwal, Fasiha
El-Serag, Hashem B.
Kramer, Jennifer R.
INFECTIOUS DISEASES AND THERAPY, 2020, 9 (02) : 355 - 365
[23] Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan
Toyoda, Hidenori
Atsukawa, Masanori
Takaguchi, Koichi
Senoh, Tomonori
Michitaka, Kojiro
Hiraoka, Atsushi
Fujioka, Shinichi
Kondo, Chisa
Okubo, Tomomi
Uojima, Haruki
Tada, Toshifumi
Yoneyama, Hirohito
Watanabe, Tsunamasa
Asano, Toru
Ishikawa, Toru
Tamai, Hideyuki
Abe, Hiroshi
Kato, Keizo
Tsuji, Kunihiko
Ogawa, Chikara
Shimada, Noritomo
Iio, Etsuko
Deguchi, Akihiro
Itobayashi, Ei
Mikami, Shigeru
Moriya, Akio
Okubo, Hironao
Tani, Joji
Tsubota, Akihito
Tanaka, Yasuhito
Masaki, Tsutomu
Iwakiri, Katsuhiko
Kumada, Takashi
JOURNAL OF GASTROENTEROLOGY, 2018, 53 (12) : 1276 - 1284
[24] US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection
Boyd, Sarita D.
Tracy, LaRee
Komatsu, Takashi E.
Harrington, Patrick R.
Viswanathan, Prabha
Murray, Jeff
Sherwat, Adam
CLINICAL DRUG INVESTIGATION, 2017, 37 (04) : 317 - 326
[25] An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection
Lee, Youn Jae
Heo, Jeong
Kim, Do Young
Chung, Woo Jin
Tak, Won Young
Kim, Yoon Jun
Paik, Seung Woon
Sim, Eungeol
Kulasingam, Susila
Talwani, Rohit
Haber, Barbara
Hwang, Peggy
CLINICAL AND MOLECULAR HEPATOLOGY, 2019, 25 (04) : 400 - 407
[26] Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects
Hsieh, Yi-Chung
Lin, Chih-Lang
Hung, Chao-Hung
Chen, Chien-Hung
Tung, Shui-Yi
Lin, Chun-Yen
Hu, Tsung-Hui
Lu, Sheng-Nan
Chien, Rong-Nan
Sheen, I-Shyan
JOURNAL OF VIRAL HEPATITIS, 2020, 27 (05) : 505 - 513
[27] Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation
Miuma, Satoshi
Miyaaki, Hisamitsu
Soyama, Akihiko
Hidaka, Masaaki
Takatsuki, Mitsuhisa
Shibata, Hidetaka
Taura, Naota
Eguchi, Susumu
Nakao, Kazuhiko
HEPATOLOGY RESEARCH, 2018, 48 (12) : 1045 - 1054
[28] Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers
Feng, Hwa-Ping
Caro, Luzelena
Fandozzi, Christine
Chu, Xiaoyan
Guo, Zifang
Talaty, Jennifer
Panebianco, Deborah
Dunnington, Katherine
Du, Lihong
Hanley, William D.
Fraser, Iain P.
Mitselos, Anna
Denef, Jean-Francois
De Lepeleire, Inge
de Hoon, Jan N.
Vandermeulen, Corinne
Marshall, William L.
Jumes, Patricia
Huang, Xiaobi
Martinho, Monika
Valesky, Robert
Butterton, Joan R.
Iwamoto, Marian
Yeh, Wendy W.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (04)
[29] Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Randomized Trial
Dore, Gregory J.
Altice, Frederick
Litwin, Alain H.
Dalgard, Olav
Gane, Edward J.
Shibolet, Oren
Luetkemeyer, Anne
Nahass, Ronald
Peng, Cheng-Yuan
Conway, Brian
Grebely, Jason
Howe, Anita Y. M.
Gendrano, Isaias N.
Chen, Erluo
Huang, Hsueh-Cheng
Dutko, Frank J.
Nickle, David C.
Bach-Yen Nguyen
Wahl, Janice
Barr, Eliav
Robertson, Michael N.
Platt, Heather L.
ANNALS OF INTERNAL MEDICINE, 2016, 165 (09) : 625 - +
[30] Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
Liu, Jinyu
Guo, Min
Ke, Lei
You, Ruxu
FRONTIERS IN PUBLIC HEALTH, 2022, 10

← 1 2 3 4 5 →